Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 2/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675039 | 0.96 | AGXT (0.52) | AGXTAOC3GGPS1MAOACYP11B1 | |
| SCHEMBL16675051 | 0.96 | AGXT (0.52) | AGXTAOC3GGPS1MAOACYP11B1 | |
| SCHEMBL13762847 | 0.81 | BCL2 (0.53) | AGXTTAAR1PRKCIBCL2 | |
| SCHEMBL2843937 | 0.80 | AGXT (0.59) | AGXTAOC3GGPS1MAOACYP11B1 | |
| SCHEMBL1337579 | 0.79 | MEN1 (0.40) | AGXTMAOATAAR1CYP19A1ALDH1A1 | |
| SCHEMBL28832201 | 0.78 | KMO (0.61) | BCL2 | |
| SCHEMBL16675058 | 0.78 | HTR7 (0.39) | AGXTAOC3 | |
| SCHEMBL31498881 | 0.78 | CALM1 (0.60) | AGXTAOC3GGPS1MAOACYP11B1 | |
| SCHEMBL31498880 | 0.78 | CALM1 (0.60) | AGXTAOC3GGPS1MAOACYP11B1 | |
| SCHEMBL9625135 | 0.78 | CALM1 (0.60) | AGXTAOC3GGPS1MAOACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104326952-A | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO | 2015-02-04 | — | — | CN | disclosed |
| CN-104277004-A | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO | 2015-01-14 | — | — | CN | disclosed |
| CN-103180300-A | Process for producing pyridazinone compound and intermediate thereof | SUMITOMO CHEMICAL CO | 2013-06-26 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | AGXT 2967/4885AOC3 259/4885GGPS1 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.